Skip to main content

How can we help you?

  • Deal or case news
  • 11-06-2014

NautaDutilh has advised ProQR Therapeutics B.V. ("ProQR"), a Dutch biotech company, with its cross-over financing round (a Series A investment) of approximately EUR 42 million. The financing round closed on 17 April 2014.

ProQR is a pre-clinical stage Dutch biotech company that develops a RNA therapy for Cystic Fibrosis based on its novel proprietary RNA correction platform. The company was founded in 2012.
The cross-over financing round in ProQR represents the largest Series A financing round of a Dutch biotech company completed in the Netherlands and is one of the largest Series A financing rounds in the US to date.

NautaDutilh's dedicated life sciences team is the legal partner of ProQR from the early beginnings of the company, providing full service legal assistance in the relevant phases in the life cycle of ProQR, from regulatory, IP, commercial, employment and corporate and capital markets support.

The NautaDutilh team assisting ProQR in the financing round was headed by Christiaan de Brauw co-managed by Bas van Hunnik and consisted of John Allen, Wijnand Bossenbroek, Petra Zijp, Paul van der Bijl, Bart van Kempen, Jochem Polderman, Paul van Dongen, Sietske Bos and Anne Noordzij.

Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.